News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Biotech/Pharma - Investor
Amedica Corporation Regains Compliance With Nasdaq Listing Requirements And Announces Capitalization Improvements 2/9/2016
Sanofi (SNY) - Full Year 2015 Results 2/9/2016
Sanofi (SNY) Delivered 2015 Business EPS Up 8.5% On A Reported Basis And Stable At Constant Exchange Rates Consistent With Guidance 2/9/2016
Why Celgene (CELG) and Gilead (GILD) Stock Can Jump 30% This Year 2/8/2016
CytRx Corporation (CYTR) Secures $40 Million Long-Term Loan Facility 2/8/2016
DiaMedica Inc. Announces Non-Brokered Private Placement 2/8/2016
Acasti Pharma Announces Share-for-Debt 2/8/2016
BioElectronics Corporation Refutes SEC Order For Administrative Proceedings 2/8/2016
Four Big Dividend Pharma Stocks to Buy that are Cheap Now 2/8/2016
QLT Inc. (QLTI) Announces Closing Of Acquisition Of Shares Of Aralez And Special Distribution To Shareholders 2/8/2016
Novavax (NVAX) Announces Exercise Of Over-Allotment Option To Purchase Additional Shares 2/8/2016
Cyclacel Pharmaceuticals, Inc. (CYCC) Announces Receipt Of Nasdaq Staff Determination; Company To Request Hearing 2/8/2016
Three Companies That Are Just as Great as Gilead (GILD) 2/5/2016
GlaxoSmithKline (GSK) CEO Asks Investors to Give Him Three Years to Turn Around Consumer Health Unit Before Considering a Break Up 2/5/2016
NovaDel Pharma (NVD) Reports Resolution Of Contingent Liabilities 2/5/2016
Zimmer Biomet Holdings Announces Launch Of Secondary Offering Of Common Stock And Concurrent Share Repurchase From Selling Stockholders 2/5/2016
SciClone Pharmaceuticals, Inc. (SCLN) Announces Final Resolution With The Securities And Exchange Commission And The Department Of Justice 2/5/2016
Edwards Lifesciences (EW) Announces $325 Million Accelerated Share Repurchase 2/5/2016
Edwards Lifesciences (EW) Announces $325 Million Accelerated Share Repurchase 2/5/2016
Agile Therapeutics, Inc. Announces Full Exercise Of Option To Purchase Additional Shares By Underwriters 2/5/2016
Genmab A/S (GEN.CO) Release: Major Shareholder Announcement 2/5/2016
Vitrolife (VITR.ST): Report On Operations 2015: Continued Profitable Growth 2/5/2016
Biostar Pharmaceuticals, Inc. (BSPM) To Effect Reverse Stock Split 2/5/2016
Phagelux Announces Expansion Capital And Other Updates 2/5/2016
HEALTHSOUTH Announces Launch Of Exchange Offers For Its Outstanding Unregistered 5.75% Senior Notes Due 2024 And 5.75% Senior Notes Due 2025 2/5/2016
Regeneron (REGN) Stock Rocks, but Vertex (VRTX), Medivation (MDVN) & Jazz Pharma (JAZZ) Roll 2/4/2016
Sinovac Biotech Ltd. (SVA) Announces Receipt of Competing Non-Binding "Going Private" Proposal 2/4/2016
Discovery Laboratories (DSCO) Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 2/4/2016
Capstone Therapeutics (CAPS) Announces Existing Shareholder Decision Not To Extend Exclusive Due Diligence Period 2/4/2016
Quotient Limited (QTNTU) Announces Proposed Underwritten Offering Of Ordinary Shares 2/4/2016
CohBar Engages Torrey Hills Capital 2/4/2016
Spotlight Innovation Updates Its Company Overview For Prospective Buyers Of Its Shares, Investors And Current Shareholders 2/4/2016
ImmuCell (ICCC) Announces Closing Of $5.9 Million Public Offering Of Common Stock 2/4/2016
Q Biomed Provides A Corporate Update 2/4/2016
Three Biotech Stocks You Don't Have to Constantly Monitor 2/3/2016
Insulet (PODD) To Divest Neighborhood Diabetes Supplies Business 2/3/2016
Jaguar Animal Health, Inc. Prices 2,000,000 Common Share Offering 2/3/2016
Hemispherx (HEB) Introduces A Voluntary Stock Purchase Plan To Create Shareholder Value 2/3/2016
Relypsa (RLYP) Announces New Employment Inducement Grants 2/3/2016
Acelity Announces Pricing Of $400 Million Of First Lien Senior Secured Notes 2/3/2016
Sarepta (SRPT) Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 2/3/2016
Immunotec Announces Issuance Of Bonus Shares 2/3/2016
Pacgen Closes Private Placement Financing 2/3/2016
Gilead (GILD) Announces Declaration Of Q1 Cash Dividend And Increases To Shareholder Return Programs 2/3/2016
Bio-Techne (TECH) Declares Dividend 2/2/2016
DiagnoCure (CUR) Reports Recommendations From Two Independent Proxy Advisory Firms Favorable To The PCA3 Asset Sale And To The Reduction Of The Stated Capital 2/2/2016
OXIS International, Inc. (OXIS) Chairman And CEO Tells Shareholders Biotech Company Making 'Substantial Progress' With Lead Cancer Drug, Drawing Closer To NASDAQ Listing 2/2/2016
Pozen (POZN) Announces Stockholder Approval Of Its Transaction With Tribute Pharmaceuticals Canada Inc. 2/2/2016
Galapagos (GLPG.BR) Receives Transparency Notification From Wellington Management Group LLP 2/2/2016
St. Jude Medical (STJ) Announces 2016 Annual Analyst And Investor Meeting 2/2/2016
With Almost $200 Million in the Bank, WAVE Life Sciences (WVE) Plans Six Clinical Programs in Three Years 2/1/2016
Echo Therapeutics (ECTE) Announces Entry Into Definitive Agreements For The Sale Of Up To $5.1 Million Of Convertible Notes And Warrants 2/1/2016
Why 2016 Could be a Tough One for St. Jude Medical (STJ) 2/1/2016
Novavax (NVAX) Announces Closing Of $300 Million Offering Of Convertible Senior Notes Due 2023 2/1/2016
Aurobindo Pharma (AUROBINDOP.BO) Shares Fall On FDA Concerns 2/1/2016
Acelity Announces Proposed Private Offering Of $400 Million Of First Lien Senior Secured Notes 2/1/2016
Centene Corporation Announces Pricing Of Senior Notes Offering 1/29/2016
Number Of Outstanding Shares In Elekta AB (SE:EKTAB) 1/29/2016
ImmuCell (ICCC) Announces Pricing Of $5.9 Million Public Offering Of Common Shares 1/29/2016
Qiming To Close Fifth U.S. Dollar Venture Fund With $650 Million 1/28/2016
Two Small Biotechs That May Have a Big 2016 1/28/2016
Novartis AG (NVS) Taps Former Hospira CEO to Rescue Alcon (ACL) 1/28/2016
Pershing Square’s Bill Ackman Writes Letter of Apology to Investors, Regrets Investing so Heavily into Valeant (VRX) 1/28/2016
Biotech 2016: Now Starts the Hangover 1/28/2016
Ushio America Announces Strategic Investment In Fixture Manufacturer, American Green Technology 1/28/2016
Baxalta (BXLT) Announces Pricing Of Secondary Offering Of Common Stock 1/28/2016
Shire (SHPG) Assigned Investment Grade Credit Ratings By Moody's And S&P 1/28/2016
Amarantus BioSciences Announces $1M Investment 1/28/2016
Centene Corporation Announces Proposed Senior Notes Offering 1/27/2016
Venaxis, Inc. (APPY) Announces Transaction With Strand Life Sciences 1/27/2016
Batu Biologics Issues Shareholder Update On Upcoming Milestones For 2016 1/27/2016
Halozyme (HALO) Announces Closing Of $150 Million Royalty-Backed Debt Financing 1/26/2016
Becton, Dickinson and Company (BDX) Board Declares Dividend 1/26/2016
Novavax (NVAX) Prices $300 Million Of Convertible Senior Notes Due 2023 1/26/2016
IntelliCyt Announces Record 2015 Sales 1/26/2016
EnteroMedics (ETRM) Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 1/25/2016
NanoViricides, Inc. (NNVC.PK) 2015 Annual Shareholders Meeting Was Held On January 23, 2016 - Company Discussed Accomplishments And Future Strategy 1/25/2016
Novavax (NVAX) Announces Proposed Offering Of $200 Million Of Convertible Senior Notes Due 2023 1/25/2016
Ampio Pharmaceuticals, Inc. (AMPE) Announces 2016 Corporate Update On Thursday, January 28, 4:30pm EST 1/25/2016
Teva (TEVA) Releases Innovation And Social Responsibility Highlights 1/25/2016
AEterna Zentaris (AEZS) Announces Additional Market Purchases Of Common Shares By Executive Management 1/25/2016
Avacta Group plc Pre-Close Trading Update 1/25/2016
Abcam plc (ABC.L) Release: Half Year Trading Update 1/25/2016
Apollo Therapeutics: Consortium Of World-Leading UK Universities And Global Pharmaceutical Companies Launch £40 Million Fund To Drive Therapeutic Innovation 1/25/2016
Turing To Testify At Congressional Hearing On Drug Pricing 1/25/2016
Lixte Biotechnology Completes Private Placement Of Convertible Preferred Stock 1/25/2016
Where Pfizer (PFE)-Allergan (AGN) May Be 10 Years Down the Road 1/22/2016
Discovery Laboratories (DSCO) Announces Reverse Stock Split 1/22/2016
DiagnoCure (CUR) Announces Fourth Quarter 2015 And Year-End Results As Well As Proxy Circular Filing And Business Initiatives Following The Execution Of An Asset Purchase Agreement To Sell All Its Assets Relating To PCA3 1/22/2016
Agile Therapeutics, Inc. Announces Pricing Of Its Public Offering Of Common Stock 1/22/2016
Simavita Limited: Security Purchase Plan And Cleansing Notice 1/22/2016
AbbVie (ABBV) CEO Argues Value of Company’s Pipeline, Piques Analysts Interest 1/21/2016
Claritas Genomics: 2015 Highlights 1/21/2016
Avacta Group plc Release: Proposed Share Consolidation 1/21/2016
ZoomMed Announces The Grant Of Options 1/21/2016
Hemostemix Company Information Now Available Through S&P Capital IQ Corporation Records Program 1/21/2016
Parnell Pharmaceuticals Holdings Announces Agreement With Lincoln Park Captial Fund To Purchase Ordinary Shares 1/20/2016
Bay Area's Twist Bioscience Locks Up $61 Million Series D, $20 Million Debt Facility 1/20/2016
Simulations Plus (SLP) Announces Quarterly Cash Dividend Of $0.05 Per Share 1/20/2016
Simulations Plus (SLP) Announces Quarterly Cash Dividend Of $0.05 Per Share 1/20/2016
Reasons Pfizer (PFE) is a Bargain Now and Why It Doesn’t Want to be Known as Pfizer 1/19/2016
Accuray Inc. (ARAY) Announces Repurchases Of Convertible Debt 1/19/2016
CASI Pharmaceuticals  (CASI) Announces Initial Closing Of Its Strategic Financing With Receipt Of $10.3 Million Proceeds 1/19/2016
Mindray Medical Announces Extraordinary General Meeting Of Shareholders 1/19/2016
Osiris Therapeutics, Inc. (OSIR) Responds To Statements About The Company Recently Posted To Several Websites 1/19/2016
Great Basin Scientific Announces Update Of Series C Warrant Conversions 1/19/2016
MabVax Therapeutics, Inc. Executes A Debt Facility For Up To $10 Million 1/19/2016
Biogen (BIIB)'s Promising Pipeline Underscores CEO’s High-Risk Strategy 1/19/2016
iCo Therapeutics Terminates Employees in Radical Restructuring Move 1/19/2016
ESSA Pharma Announces Closing of US$15 Million Private Placement 1/15/2016
SQI Diagnostics To Extend Warrant Expiry 1/15/2016
BioAmber Inc. Announces Pricing Of $11.0 Million Public Offering 1/15/2016
Becton, Dickinson and Company (BDX) Announces Webcast of Annual Meeting Of Shareholders 1/15/2016
Portage Biotech Issues Letter To Shareholders 1/15/2016
Ariad (ARIA) Reports Inducement Grant To New Chief Executive Officer 1/15/2016
Agenus (AGEN) Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 1/15/2016
Key Points Amgen (AMGN) CEO Bob Bradway Made at J.P. Morgan 1/15/2016
Ardelyx (ARDX) Announces Closing Of Public Offering Including Exercise Of Underwriters' Right To Purchase Additional Shares 1/14/2016
Regen BioPharma President Harry Lander Provides Open Letter To Shareholders On Company's Progress And Developments 1/14/2016
Simavita Limited Announces Closing Of First Tranche Of Private Placement Offering 1/14/2016
BioAmber Inc. Announces Public Offering Of Common Stock 1/14/2016
2015 Was a Record Breaker for M&A in Pharma, Medical and Biotech with Deals Worth $575 Billion 1/14/2016
Gilead (GILD) Should Have Investors Giddy Over Continued HCV Dominance at J.P. Morgan 1/13/2016
Cempra Completes Public Offering Of Common Stock 1/13/2016
Adamas Pharmaceuticals (ADMS) Provides Review Of 2015 And Projected Future Milestones 1/13/2016
EnteroMedics (ETRM) Announces Closing Of $11 Million Tranche From Previously-Announced Convertible Notes Offering 1/13/2016
VolitionRX Releases Annual Shareholder Update Letter 1/13/2016
KaloBios (KBIO) Withdraws Appeal On Nasdaq Delisting 1/13/2016
Anthem Targets $3 Billion in Drug Cost Savings with Express Scripts 1/13/2016
Syros Pharmaceuticals Closes $40 Million Preferred Stock Financing 1/13/2016
Epizyme (EPZM) Announces Closing Of Public Offering Of Common Stock 1/13/2016
Adjustments Affecting BioTime (BTX) Common Share Purchase Warrants Expiring October 1, 2018 1/13/2016
Roche (RHHBY) is Favored Stock at J.P. Morgan Conference, Although Investors Remain Unmoved 1/12/2016
Amid Biotech Bloodbath, Investors Turn Their Eyes Onto Alere (ALR) at J.P. Morgan 1/12/2016
Accuracy Closes $70 Million Straight Debt Financing 1/12/2016
Tianyin Pharmaceutical Co, Inc. Received Acceptance Letter From NYSE MKT Regarding Its Plan Of Compliance With Continued Listing Requirements 1/12/2016
West Pharmaceutical Services Announces New Organizational Structure 1/12/2016
HeartWare (HTWR) Provides Corporate Updates And Announces Preliminary Revenue For Fourth Quarter 2015 1/12/2016
Ionis (IONS) Revises 2015 Financial Guidance And Provides Pipeline Update In Conjunction With J.P. Morgan Conference 1/12/2016
BioAtla Nabs $45 Million Funding Commitment From U.S. Investment Fund 1/11/2016
Covalon Technologies Ltd. Chairman Acquires Additional Shares And Warrants 1/11/2016
Rubicon Genomics, Inc. Adds New Distributors As Product Sales Continued To Accelerate In 2015 1/11/2016
aTyr Pharma Provides Corporate Update And Outlook For 2016 1/11/2016
Tesaro (TSRO) Outlines Business Priorities And Strategic Outlook For 2016 1/11/2016
Cyclacel Pharmaceuticals, Inc. (CYCC) Reviews 2015 Achievements And Announces Key Business Objectives For 2016 1/11/2016
Arbutus Biopharma (ABUS) Provides A Corporate Update And Outlines 2016 Milestones 1/11/2016
Pressure BioSciences, Inc. (BBII) Exceeds $5 Million PIPE Goal And Opens $1.25 Million Over-Subscription Amount 1/11/2016
Ironwood (IRWD) Details Strategy To Build Top-Performing Commercial Biotechnology Company 1/11/2016
Adimab LLC. Provides Update On Recent Partnerships And Milestones 1/11/2016
Alnylam (ALNY) Outlines 2016 Goals For RNAi Therapeutics Pipeline 1/11/2016
Global Genomics Company, GENEWIZ, Inc., Receives Investment 1/11/2016
OXIS International, Inc. (OXIS) Eliminates Debt In Restructuring Deal, Will Move Forward With Phase 1/Phase 2 Clinical Trial Of Cancer Drug 1/11/2016
Second Sight (EYES) Provides Business Update And Key Performance Metrics For Full Year 2015 1/11/2016
Pfizer (PFE) Expands R&D Equity Investment Strategy To Access Early-Stage Scientific Innovations 1/11/2016
Ariad (ARIA) Announces Termination Of Shareholder Rights Plan 1/11/2016
Transgenomic, Inc. (TBIO) Announces Private Placement Financing 1/11/2016
Ardelyx (ARDX) Announces Pricing Of Public Offering Of Common Stock 1/8/2016
Portola (PTLA) To Webcast Corporate Update On January 12, 2016 1/8/2016
Chiasma Reviews 2015 Accomplishments And Outlines Core Objectives For 2016 1/8/2016
NW Bio (NWBO) Issues Statement On Adverse Market Conditions And NW Bio Stock Decline 1/8/2016
Puma Biotech (PBYI) Shareholders Overwhelmingly Reject Eshelman’s Consent Solicitation 1/8/2016
Becton, Dickinson and Company (BDX) Divests BD Rx Business, Adding IV Solutions 1/8/2016
CEL-SCI (CVM) Summarizes Significant Accomplishments In 2015 And Positive Momentum For 2016 1/8/2016
Regulus (RGLS) Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 1/7/2016
PTC Therapeutics (PTCT) Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 1/7/2016
Ardelyx (ARDX) Announces Proposed Public Offering Of Common Stock 1/7/2016
Sucampo (SCMP) Provides Update To 2015 And Confirms 2016 Financial Guidance Post Closing Of R-Tech Ueno Acquisition 1/7/2016
Kindred Bio (KIN) To Provide Corporate Update 1/7/2016
Mast Therapeutics (MSTX) Provides Business Update 1/7/2016
Enzo Biochem (ENZ) Updates Corporate Developments At Annual Shareholders Meeting 1/7/2016
Epizyme (EPZM) Announces Pricing Of Public Offering Of Common Stock 1/7/2016
Acadia (ACAD) Prices Public Offering Of Common Stock 1/7/2016
Akebia (AKBA) Prices Public Offering Of Common Stock 1/7/2016
Change In The Number Of Shares And Votes In Camurus 1/7/2016
A Letter From the ChromaDex, Inc. Chief Executive Officer 1/6/2016
Fitbit (FIT) Tanks as Competition in Fitness Devices Heats Up 1/6/2016
ESSA Pharma Announces Proposed US$15 Million Private Placement 1/6/2016
Midatech Release: Pre-close Trading Update 1/6/2016
Relypsa (RLYP) Announces New Employment Inducement Grants 1/6/2016
SAGE Therapeutics (SAGE) Announces Proposed Public Offering Of Common Stock 1/6/2016
Apricus Biosciences (APRI) Announces Year-End 2015 Update And 2016 Growth Strategy 1/6/2016
Transition Therapeutics (TTH.TO) Announces Annual General Meeting Voting Results 1/6/2016
Oramed (ORMP)' Shareholder Letter 1/6/2016
Acceleron Pharma Announces Pricing Of Public Offering Of Common Stock 1/6/2016
X-Chem Established As Independent, Privately Owned Biotechnology Company 1/6/2016
ProtoKinetix Inc. (PKTX.OB) Corporate Update 1/6/2016
Acadia (ACAD) Announces Proposed Public Offering Of Common Stock 1/6/2016
Epizyme (EPZM) Announces Proposed Public Offering Of Common Stock 1/6/2016
TherapeuticsMD, Inc.  (TXMD) Announces $125 Million Offering Of Common Stock 1/6/2016
GenSpera Issues Letter To Stockholders 1/6/2016
Hologic (HOLX) Delivers Notice That Holders Of 2.00% Convertible Exchange Senior Notes Due 2037 Are Eligible To Convert 1/5/2016
CytRx Corporation (CYTR) Announces Settlement Of California Stockholder Derivative Lawsuit 1/5/2016
Eli Lilly (LLY) Announces 2016 Financial Guidance, Updates 2015 Expectations 1/5/2016
GlySens Secures $20 Million Series D 1/5/2016
Cynapsus Therapeutics (CYNA) Completes Short-Form Amalgamation With Wholly-Owned Subsidiary 1/5/2016
The Board Of Directors Of BioTie Therapies Corp. Has Approved Two Year Incentive Plan For Employees 1/5/2016
BioTie Therapies Corp.:Issuance Of Shares Pursuant To Option And Equity Incentive Plans 1/5/2016
ICON Secures Investment Grade Credit Ratings 1/5/2016
Acceleron Pharma Announces Proposed Public Offering Of Common Stock 1/5/2016
Sarepta (SRPT) Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 1/5/2016